Neuren Pharmaceuticals
Follow
Get notifications in MyBN when activity occurs.
Industry Lists
Public Companies - non WANeuren Pharmaceuticals (NEU) is a biopharmaceutical company developing therapies for brain injury, neurodevelopmental and neurodegenerative disorders.
NEU has two key drug products comprising NNZ-2566 and NNZ-2591.
NEU has operations in New Zealand, Australia and the USA.
Contact Details
Level 15, PWC Tower, 188 Quay Street, AUCKLAND New Zealand 1141
+64 9 370 0200
Lists and Charts
Share price
Closing price for the last 90 trading days
Powered by Morningstar ®
Total Shareholder Return as at 31/10/24
| Rank | Company | 1 yr | 5 yr |
|---|---|---|---|
| 655th | Neuren Pharmaceuticals | 15% | 40% |
1740 WA (and selected non WA) listed companies ranked by
1 year TSR relative to other companies with similar revenue
Powered by Morningstar ®
1 year TSR relative to other companies with similar revenue
Powered by Morningstar ®
Revenue
| Rank | Company | Revenue | |
|---|---|---|---|
| th |  | Neuren Pharmaceuticals | $234.4m |
1334 listed non wa companies ranked by revenue.
Powered by Morningstar ®
Powered by Morningstar ®
Share Transactions
Total value as at the date of the transaction
Powered by Morningstar ®
Company Activity
| NEW ROLE: Jon C Pilcher, Chief Executive Officer, Managing Director | 14 Aug 2024 |
| NEW ROLE: Joseph Basile, Non-Executive Director | 05 Aug 2024 |
| NEW ROLE: Jenny Harry, Non-Executive Director | 03 Nov 2020 |
| NEW ROLE: Patrick Davies, Non-Executive Director, Non-Executive Chairman | 03 Nov 2020 |
| NEW ROLE: Lauren Frazer, Chief Financial Officer, Company Secretary | 03 Nov 2020 |
| NEW ROLE: Jon C Pilcher, Chief Financial Officer, Company Secretary, Chief Executive Officer | 03 Nov 2020 |
| NEW ROLE: Trevor D Scott, Non-Executive Director | 03 Nov 2020 |
| NEW ROLE: Dianne Angus, Non-Executive Director | 03 Nov 2020 |
